FDA Expands Indications for Lutetium Lu 177 Vipivotide Tetraxetan to Include Patients with PSMA Positive mCRPC By Ogkologos - April 25, 2025 879 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the PSMAfore study Source RELATED ARTICLESMORE FROM AUTHOR Consensus-Defined Weight Loss Episodes Arise in Discrete Intervals, Are Enriched Around Progression and Associated with Serologic Signatures and Somatic Tumour Genotypes ESMO launches new principles for humanising scientific reporting to strengthen the communication of cancer research Clinical Activity of Talazoparib Plus Enzalutamide Demonstrated in Patients with High-Volume mHNPC, but Without Clear Benefit Over Enzalutamide in Biomarker-Unselected Population MOST POPULAR Addressing Cancer Pain with Complementary Methods (Part 2) April 10, 2023 ESMO Breast Cancer Congress 2023 April 17, 2023 Pumpkin Season! October 27, 2020 Man Born Without Legs Proves He’s Greater Than Any Obstacle He’s... December 5, 2021 Load more HOT NEWS Analysis Patterns of Systemic Anticancer Treatment at End-of-Life Indicates No Changes... Immune-Modulating SBRT Plus Anti-PD-L1 May Convert Immune-Cold ER-positive, HER2-negative EBC Into... Help Desk for Oncologists Treating People with a Rare Leukemia Pays... Aiming to support a robust regulatory ecosystem for driving cancer research...
